Wang Jing, Yin Shuping, Chen Kewei
Department of Obstetrics and Gynecology, Affiliated Hospital of Chifeng University, Chifeng, China.
Department of Obstetrics and Gynecology, Changxing County People's Hospital, Huzhou, China.
Gland Surg. 2022 Oct;11(10):1639-1646. doi: 10.21037/gs-22-459.
The systemic immune-inflammation index (SII) has been proven to be related to the prognoses of multiple malignant tumors. However, there are still few studies on the relationship between the SII and the effect of neoadjuvant chemotherapy in patients with ovarian cancer. It is of great significance to predict the efficacy of neoadjuvant chemotherapy in patients with ovarian cancer. Our study was aimed at determining the predictive value of the SII for the efficacy of neoadjuvant chemotherapy and prognosis in patients with stage III ovarian cancer.
A total of 102 patients with stage III ovarian cancer treated in Tongji Hospital of Tongji University from January 2017 to January 2019 were retrospectively collected. According to the level of the SII before neoadjuvant chemotherapy, patients were divided into the high SII group and low SII group. We compared the effect of neoadjuvant chemotherapy between the 2 groups, and observed the progression-free survival and mortality of patients in the 2 groups after 3 years follow-up.
Compared with patients in the low SII group, the complete response rate of patients in the high SII group decreased significantly after neoadjuvant chemotherapy (13.73% 45.10%, P=0.001), and the progressive disease rate increased (19.61% 1.96%, P=0.011). The SII had certain value in predicting the inefficacy of neoadjuvant chemotherapy in patients with stage III ovarian cancer, and the area under the curve was 0.655 (95% CI: 0.548-0.762, P=0.007). The progression-free survival of patients in the high SII group was shorter than that of patients in the low SII group (P<0.001), and the overall survival rate of patients in the high SII group was lower (47.06% 70.59%, P=0.016). The SII had predicting value for the postoperative death of ovarian cancer patients after neoadjuvant chemotherapy, and the area under the curve was 0.646 (95% CI: 0.537-0.756, P=0.012). Multivariate regression analysis showed that higher SII was a risk factor for death in ovarian cancer patients after neoadjuvant chemotherapy (OR: 2.700, P=0.017).
A high SII was a predictor of inefficacy of neoadjuvant chemotherapy in patients with stage III ovarian cancer and was related to poor prognosis.
全身免疫炎症指数（SII）已被证明与多种恶性肿瘤的预后相关。然而，关于SII与卵巢癌患者新辅助化疗疗效之间关系的研究仍然较少。预测卵巢癌患者新辅助化疗的疗效具有重要意义。我们的研究旨在确定SII对III期卵巢癌患者新辅助化疗疗效及预后的预测价值。
回顾性收集2017年1月至2019年1月在同济大学附属同济医院接受治疗的102例III期卵巢癌患者。根据新辅助化疗前SII水平，将患者分为高SII组和低SII组。比较两组新辅助化疗的效果，并观察两组患者随访3年后的无进展生存期和死亡率。
与低SII组患者相比，高SII组患者新辅助化疗后的完全缓解率显著降低（13.73%对45.10%，P = 0.001），疾病进展率升高（19.61%对1.96%，P = 0.011）。SII在预测III期卵巢癌患者新辅助化疗无效方面具有一定价值，曲线下面积为0.655（95%CI：0.548 - 0.762，P = 0.007）。高SII组患者的无进展生存期短于低SII组患者（P < 0.001），高SII组患者的总生存率较低（47.06%对70.59%，P = 0.016）。SII对新辅助化疗后卵巢癌患者的术后死亡具有预测价值，曲线下面积为0.646（95%CI：0.537 - 0.756，P = 0.012）。多因素回归分析显示，较高的SII是新辅助化疗后卵巢癌患者死亡的危险因素（OR：2.700，P = 0.017）。
高SII是III期卵巢癌患者新辅助化疗无效的预测指标，且与不良预后相关。
